{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:24:17Z","timestamp":1789169057917,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018955","name":"NIHR Leeds Musculoskeletal Biomedical Research Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaut.2026.103592","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:15:43Z","timestamp":1781705743000},"page":"103592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A\/F inhibition"],"prefix":"10.1016","volume":"162","author":[{"given":"Antonio","family":"Tonutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Voiculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trunfio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"Abacar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Altaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Vandevelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Meridor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kave","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Quartuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaut.2026.103592_bib1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13075-024-03401-x","article-title":"Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort","volume":"26","author":"Ramonda","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2026.103592_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1435599","article-title":"Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis","volume":"15","author":"Ramonda","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2026.103592_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"19","key":"10.1016\/j.jaut.2026.103592_bib4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaut.2026.103592_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.04.006","article-title":"Interleukin-17 and innate immunity in infections and chronic inflammation","volume":"60","author":"Isailovic","year":"2015","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.jaut.2026.103592_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40257-022-00686-z","article-title":"Candida infection associated with Anti-IL-17 medication: a systematic analysis and review of the literature","volume":"23","author":"Yamanaka-Takaichi","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103592_bib7","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1080\/09546634.2022.2104442","article-title":"Invasive Aspergillus infection of middle ear in a patient treated with secukinumab, methotrexate, and corticosteroids for psoriasis and psoriatic arthritis","volume":"33","author":"Rob","year":"2022","journal-title":"J. Dermatol. Treat."},{"issue":"9","key":"10.1016\/j.jaut.2026.103592_bib8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2026.103592_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155715","article-title":"Divergent functions of IL-17-family cytokines in DSS colitis: insights from a naturally-occurring human mutation in IL-17F","volume":"148","author":"Zhou","year":"2021","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.jaut.2026.103592_bib10","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese","year":"2024","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103592_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamadermatol.2023.5051","article-title":"Treatment of severe palmoplantar pustular psoriasis with bimekizumab","volume":"160","author":"Passeron","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103592_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/1346-8138.14815","article-title":"Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases","volume":"46","author":"Pinter","year":"2019","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103592_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","article-title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway","volume":"85","author":"Bissonnette","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"8","key":"10.1016\/j.jaut.2026.103592_bib14","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/MIB.0b013e318286fa1c","article-title":"TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis","volume":"19","author":"Wedebye Schmidt","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jaut.2026.103592_bib15","article-title":"Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2026.103592_bib16","article-title":"Late-onset Spondylarthritis presenting as Glucocorticoid-resistant Polymyalgia Rheumatica: a hitherto underappreciated entity where TNF or IL-17 Blockade may have a Therapeutic Role","author":"Abacar","year":"2025","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103592_bib40","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jaut.2026.103592_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12852","article-title":"Multiple paradoxical reactions during ixekizumab therapy","volume":"32","author":"Pirro","year":"2019","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.jaut.2026.103592_bib18","first-page":"106","article-title":"Palmoplantar pustulosis under secukinumab in two patients without psoriasis","volume":"20","author":"Penalba-Torres","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"6","key":"10.1016\/j.jaut.2026.103592_bib19","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1097\/RHU.0000000000001076","article-title":"Paradoxical pustular psoriasis in a patient with psoriatic arthritis on secukinumab treatment","volume":"26","author":"Abbruzzese","year":"2020","journal-title":"J. Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.jaut.2026.103592_bib20","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1111\/1346-8138.14463","article-title":"Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis","volume":"45","author":"Takahashi","year":"2018","journal-title":"J. Dermatol."},{"issue":"11","key":"10.1016\/j.jaut.2026.103592_bib21","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1111\/jdv.15714","article-title":"First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab","volume":"33","author":"Sadik","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jaut.2026.103592_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1364127","article-title":"Paradoxical reaction to IL-17A inhibitor: a case report and literature review","volume":"11","author":"Ren","year":"2024","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.jaut.2026.103592_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.31138\/mjr.110525.ary","article-title":"Secukinumab-induced severe palmoplantar psoriasis treated with Guselkumab: a case report","volume":"36","author":"Al-Homood","year":"2025","journal-title":"Mediterr. J. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103592_bib24","article-title":"Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases","author":"M\u00f6ssner","year":"2020","journal-title":"Eur. J. Dermatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103592_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/ijd.16064","article-title":"Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review","volume":"62","author":"Lu","year":"2023","journal-title":"Int. J. Dermatol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103592_bib26","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/1744666X.2023.2272049","article-title":"Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis","volume":"19","author":"Tsiogkas","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103592_bib27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40257-024-00876-x","article-title":"Efficacy and safety of brodalumab, an Anti-interleukin-17 receptor A monoclonal antibody, for palmoplantar pustulosis: 16-week results of a randomized clinical trial","volume":"25","author":"Okubo","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103592_bib28","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S2665-9913(22)00334-4","article-title":"Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders","volume":"5","author":"Macleod","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2026.103592_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.622770","article-title":"Clinical trials supporting the role of the IL-17\/IL-23 axis in axial spondyloarthritis","volume":"12","author":"Ceribelli","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2026.103592_bib30","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.jaut.2026.103592_bib31","first-page":"3573","article-title":"Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling","volume":"119","author":"Eyerich","year":"2009","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.jaut.2026.103592_bib32","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2026.103592_bib33","article-title":"IL-17C as a driver of inflammation in psoriasis","volume":"23","author":"Han","year":"2025","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.jaut.2026.103592_bib34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jdv.16126","article-title":"IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema","volume":"34","author":"Lauffer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103592_bib35","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jaut.2026.103592_bib36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2174\/1381612824666180116095658","article-title":"The role of colchicine in the treatment of autoinflammatory diseases","volume":"24","author":"Liantinioti","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.jaut.2026.103592_bib37","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2665-9913(24)00225-X","article-title":"Advancing personalised precision treatment for still's disease based on molecular characteristics and disease progression","volume":"7","author":"Shen","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103592_bib38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/art.41635","article-title":"Association of the leukocyte immunoglobulin-like receptor A3 gene with neutrophil activation and disease susceptibility in adult-onset still's disease","volume":"73","author":"Wang","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2026.103592_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155897","article-title":"Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions","volume":"156","author":"Sachen","year":"2022","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.jaut.2026.103592_bib41","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103592_bib42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103592_bib43","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaad.2018.12.018","article-title":"TNF-\u03b1 inhibitor-induced psoriasis: a decade of experience at the Cleveland clinic","volume":"83","author":"Mazloom","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103592_bib44","article-title":"Paradoxical psoriasis with IL-17 inhibitors","volume":"8","author":"Singla","year":"2024","journal-title":"Rheumatol. Advanc. Pract."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:35:44Z","timestamp":1785879344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S0896841126000703"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103592","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A\/F inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103592"}}